PUBLIC COMPANY
save$SLNSilence Therapeutics plc
$SLNLondon, GBupdated 2mo ago
Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Study to Assess SLN124 in Patients With Polycythemia Vera
- phase2Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
- phase1Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)
- phase1A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome
🐶 Hiring Signal
News
- Disc sets up polycythemia vera challenge but Silence maintains leadThe polycythemia vera field is heating up, with Disc Medicine and Silence Therapeutics each advancing next-generation therapies, playing catch-up to Takeda and Protagonist Therapeutics, who won the…biospace · 22d ago
- Novartis, Ionis drug failure spurs questions about an emerging class of heart medicinesPelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a surprise result with important implications for cardiovascular drug rese…biopharma_dive · 28d ago
- Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccinesSome analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to level…biopharma_dive · 1mo ago
- Silence causes uproar in rare blood cancer space as data sets high bar for competitorsThe mid-stage win of Silence Therapeutics’ siRNA drug in polycythemia vera validates the therapeutic approach of similar assets in development—but also sets a high standard for therapies from Taked…biospace · 1mo ago
- STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatmentThe FDA has rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis.stat · 1mo ago
- STAT+: FDA panel to weigh Grail’s Galleri testChina reins in its biotech innovation engine, radiopharma boom meets unexpected hurdles, and more news from The Readoutstat · 1mo ago
- STAT+: Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trialA pill from Sionna Therapeutics provided no added benefit when combined with Vertex's cystic fibrosis blockbuster Trikafta, a blow to the biotech.stat · 1mo ago
- STAT+: Heart failure drug from Tenax Therapeutics fails in pivotal studyA Tenax Therapeutics drug designed to treat a type of heart failure associated with high blood pressure in the lungs failed in a closely watched study.stat · 1mo ago
- Silence spells out Phase 2 success for gene-silencing drug in rare blood cancerSilence Therapeutics is set to advance its siRNA drug for the rare blood disorder polycythemia vera (PV) into Phase 3 following a successful mid-stage trial. Silence said Monday that its drug ...endpoints · 1mo ago
- STAT+: Silence Therapeutics aims at Takeda with new data in rare blood cancerA rare blood cancer drug from Silence Therapeutics showed strong results in a trial, potentially setting it up to compete with a Takeda medicine.stat · 1mo ago
Data sources
last refreshed 11m ago
Found something off?
comments(0)
5-min edit window · permanent after that